Peripheral neuropathy decisions — 2025

The Veteran was granted a special monthly compensation (SMC) based on entitlement to SMC(l) for being so helpless as to be in need of regular aid and attendance due to his service-connected disabilities, effective December 17, 2010.

The Board granted an initial 20 percent disability rating for each of the Veteran's right and left lower extremity sciatic and femoral nerve diabetic peripheral neuropathies.

The appeal was dismissed due to the Veteran's death while it was pending.

The Board remands the claim for service connection of right and left lower extremity peripheral neuropathy, to include as due to exposure to herbicide agents (Agent Orange), for further development.

The Board remands the claim of service connection for right upper extremity peripheral neuropathy as secondary to PTSD due to an inadequate medical opinion and a need for further development.

The Board denied service connection for an upper stomach condition and peripheral neuropathy of all extremities, finding that the conditions were not directly related to the Veteran's presumed exposure to Agent Orange in Vietnam.

The appeal was dismissed due to the Veteran's death during the pendency of the appeal.

The Board granted an increased 40 percent rating for small fiber peripheral neuropathy of the right and left lower extremities.

The Board granted earlier effective dates for the grant of service connection for diabetes mellitus II with erectile dysfunction and certain diabetic peripheral neuropathies, but denied them for others.

The Board denied the claims for service connection for diabetes mellitus type II, bladder cancer, left and right leg peripheral neuropathy as there was no evidence of in-service incurrence or aggravation of a disease or injury, and no causal relationship between the current disabilities and the Veteran's military service.

The Board remands the matter for further development, including obtaining additional evidence and a new VA examination to determine if the Veteran's BLE disabilities are related to in-service environmental exposures.

The Board granted earlier effective dates of January 21, 2003, for the award of service connection for diabetic peripheral neuropathy in both upper extremities and denied higher disability ratings.

The Board remands the claims for service connection for bilateral upper and lower extremity peripheral neuropathy as additional development is necessary.

The Board granted service connection for bilateral upper and lower extremity peripheral neuropathy, finding a nexus to the Veteran's in-service herbicide agent exposure.

The Board remands the claims for service connection for migraine headaches and peripheral neuropathy, to include as due to Persian Gulf War service and/or service-connected disabilities, for further development of evidence.

The Board granted earlier effective dates of September 16, 1983 for the lumbar spine disability and related conditions, but denied increased ratings for peripheral neuropathy in both lower extremities and a rating for radiculopathy.

The Board remands the claims for service connection for right lower extremity peripheral neuropathy, right upper extremity peripheral neuropathy, and left lower extremity peripheral neuropathy due to a pre-decisional duty to assist error in failing to obtain an adequate medical opinion.

The Board denied service connection for various conditions, including bilateral knee, hearing loss, tinnitus, skin rash, and sleep apnea. The Veteran was granted a 20 percent rating for diabetic neuropathy of the femoral nerve in both lower extremities.

The Board remands the issues for further development, including obtaining a new TERA memorandum and appropriate VA opinions to determine if the Veteran's claimed conditions are related to his service exposure.

The Board denied an earlier effective date for the grant of service connection for peripheral neuropathy of both upper extremities and remanded increased rating claims for peripheral neuropathy of all four extremities as well as a higher rating claim for prostate cancer with erectile dysfunction.